鲁索替尼能否破坏 TET2 和 IDH2 驱动的克隆造血？
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis?
发表日期：2024 Oct 04
作者：
Elmira Khabusheva, Margaret A Goodell
来源：
Cancer Discovery
摘要：
在本期中，Waarts 及其同事开发了一种先进的离体 CRISPR 筛选平台，用于识别克隆造血 (CH) 中的漏洞。这一独特的系统使作者能够确定 IDH2 和 TET2 CH 突变、组蛋白去甲基化酶和改变的细胞因子信号传导之间的联系，从而使鲁索替尼能够靶向消除 CH 克隆，从而为预防恶性肿瘤的发展提供可能的途径。参见 Waarts 等人的相关文章，第 17 页。 1860.©2024 美国癌症研究协会。
In this issue, Waarts and colleagues developed an advanced ex vivo CRISPR screening platform to identify vulnerabilities in clonal hematopoiesis (CH). This unique system allowed the authors to identify a link between IDH2 and TET2 CH mutations, histone demethylases, and altered cytokine signaling, which enabled targeting by ruxolitinib leading to the elimination of CH clones, offering a possible path for preventing the development of malignancy. See related article by Waarts et al., p. 1860.©2024 American Association for Cancer Research.